

**Audrey's Life Science Meeting Picks for Feb. 26, 2017 – April 2017**  
**Complimentary Service of AudreysNetwork.com**  
**Feb. 26, 2017**

\*\*\*\*\*

**Bio2Device Group, Tuesday Morning, Feb. 28, 2017**

Topic: "Machine Learning as the backbone for Predictive Failure Analytics of Devices "  
Speaker: Ramki Pitchuiyer , Founder and CEO, eKryp  
Date and Time: Tuesday, Feb. 28, 2017, 8:30 am-10:30 am  
Location: Sunnyvale City Council Chambers- 456 West Olive Ave., Sunnyvale  
No fees or registration required for morning meetings.

**Topic Description**

Unprecedented growth in IoT and connected devices is producing a variety of challenges and opportunities. The advent of machine learning along with Big Data technology, coupled with efficient cloud based deep data storage mechanisms and parallel processing frameworks, has allowed us to come up with ways to increase uptime of critical machines. The presentation details the journey into using machine learning for predictive failure analytics and lessons learnt to drive such a solution within medical and biotech enterprises. With an increasing number of products that have embedded sensors and the ability to communicate, it is becoming imperative to monitor the usage, condition, and operations of these assets in real time. Furthermore, the rapid growth in data for offline and real time analytics enables failure prediction, preventive maintenance, and optimization of operations. We will discuss how machine learning can enhance the customer experience and lower service costs. The discussion will take a case study and discuss how enterprises can avoid unscheduled downtime and increase uptime through data driven diagnostics. As an added benefit, such a solution would also optimize parts inventory plan, improve overall service operations, and increase the Overall Equipment Effectiveness (OEE).

**Speaker Bio**

Ramki Pitchuiyer is currently the founder and CEO of eKryp, a stealth-mode start up focused on using machine learning and deep analytics to increase the uptime of critical machines in the industrial sub segments such as medical devices, biotech equipment, and money machines. Prior to eKryp, Ramki co-founded Paloras in 2011, which focuses on helping clients transform business processes in Product Life Cycle Management, Supply Chain and Customer Experience. In 2013 and 2014, Paloras was awarded Top 100 Businesses in the Bay Area by the San Francisco Business journal.

Ramki began his career as a programmer at Tata Unisys and Unisys, and later moved to management consulting at Ernst & Young. He then held senior management roles at Oracle and Ernst & Young prior to venturing out with Paloras and eKryp. At Oracle, he led consulting solution organization spanning several major industries: High Tech, Aerospace & Defense, Automotive, Industrial Manufacturing, CPG, and Oil & Gas. Prior to that he was engaged in major system integration and implementation for Fortune 500 companies and managed multiple \$60M+ global programs with teams across continents.

Ramki holds an MBA from the Anderson Graduate School of Management at UCLA, and a B.S in Electrical and Electronics Engineering from BITS, Pilani in India. Ramki has been mentoring youth in science, technology and mathematics since 2007 as FIRST robotics coach, math coach and Western Regional robotics volunteer.

\*\*\*\*\*

**HBA Webinar, Tuesday, Feb. 28, 2017**

## Webinar - Creating a Feedback-Rich Culture

### Featured speakers

Juliana Wood

Assoc. director online learning resources

Healthcare Businesswomen's Association

Deborah Riegel

Principal and director of learning

The Boda Group

Priya Nalkur-Pai

Leadership coach

The Boda Group

Date and Time: Tuesday, February 28, 1:00 – 2:00 pm EST, 10:00 – 11:00 am PT

### Agenda

12:00 - 12:05 PM Welcome and introductions

12:05 - 12:50 PM Presentation

12:50 - 1:00 PM Q&A session; thank you and closing greetings

### Pricing

Registration Name Price Level Regular

1 - Individual registration Member \$25.00

1 - Individual registration Non-Member \$35.00

2 - Group of 15 registrations Member \$300.00

2 - Group of 15 registrations Non-Member \$300.00

3 - Group of 25 registrations Member \$500.00

3 - Group of 25 registrations Non-Member \$500.00

4 - Group of 50 registrations Member \$875.00

4 - Group of 50 registrations Non-Member \$875.00

5 - Group of 100 registrations Member \$1500.00

5 - Group of 100 registrations Non-Member \$1500.00

Register at <https://my.hbanet.org/MyHBA/EventDetails.aspx?MeetingID=18379AF5-B3C7-E611-A5C2-0050569C00A7>

Please note this webinar will take place from 12:00 – 1:00 PM ET. Please convert into your local time zone and mark your calendar accordingly.

### Event contact

Juliana Wood

973-575-0606 ext. 1

### Competencies

2. Communicates effectively
8. Builds relationships and teams

### Webinar Description

Feedback helps leaders and team members align personal behaviors with organizational goals, reinforce norms and develop themselves and others in ways that create positive business outcomes. Studies show that professionals who work in organizations with a strong culture of feedback experience more engagement, greater job satisfaction, increased resiliency and even reduced pain and inflammation. When leaders create a feedback-rich culture where they offer helpful feedback in a timely manner — and are open to receiving it themselves — everyone benefits.

In this participatory workshop, you'll learn to convey information in a way that can be heard, digested and applied moving forward, creating a positive environment that

fosters learning and receptivity to feedback. You'll discover how to apply feedback techniques to increase positive behaviors and performance, how to adapt your feedback style to different communication styles and when to give feedback (and when not to). Specific techniques for dealing with feedback-resistant employees will also be provided.

Gain confidence in this key leadership skill by practicing giving and receiving feedback with other participants. Leave this session ready to build stronger workplace relationships.

#### Registration information

Event is open to: HBA members and nonmembers

Online registration available until one hour before the live broadcast begins.

This webinar is nonrefundable.

#### Learning objectives

1. Use a proven four-step model for giving effective feedback
2. Adapt feedback style to different communication styles
3. Apply seven specific techniques for dealing with feedback-resistant employees

\*\*\*\*\*

#### **Palo Alto AWIS, Tuesday Evening, Feb. 28, 2017**

Topic: "Inside the World of Engineering and Scientific Consulting "

Speakers: Meredith Sellers, PhD, is a Managing Engineer, Farzana Ansari, PhD, is an Associate and Jenny Irwin is a University Recruiting Manager in Human Resources Date and Time: Tuesday, Feb. 28, 2017, 7:00 – 9:00 pm

7:00-7:30: Networking dinner

7:30-7:45: Announcements

7:45-9:00: Workshop

Location: PARC Auditorium, 3333 Coyote Hill Rd, Palo Alto, CA 94304, USA

Free for members; \$15 pre-registration, and \$25 at the door for non-member

Register at <http://www.brownpapertickets.com/event/2881484>

#### Topic Description

Are you looking to transition into the scientific and engineering consulting industry? Do you want to solve real world, applied problems and work with diverse clients from the private and public sectors? Join Exponent Scientists, Engineers, and Recruiters to learn about technical consulting, find out how your scientific skills fit into the industry and talk about the challenges and rewards of a career in technical consulting.

#### Speaker Bios

Meredith Sellers, PhD, is a Managing Engineer who aids clients in materials analysis and incident/accident investigation pertaining to oil and gas pipelines, chemical process safety, and consumer and industrial electronics.

Farzana Ansari, PhD, is an Associate who aids clients in matters related to the mechanics of materials, medical device product failure, and polymer fracture and fatigue.

Jenny Irwin is a University Recruiting Manager in Human Resources and helps to lead efforts in recruiting and people development within Exponent.

\*\*\*\*\*

**GGPF, Wednesday Evening, March 1, 2017**

Topic: "Blocky Functionalization of Thermo-Reversible sPS and PEEK Gels"

Speaker: Prof. Robert B. Moore, Dept. of Chemistry, Virginia Tech

Date and Time: Wednesday, March 1, 6:00 pm

6:00 PM social hour

7:00 PM dinner

8:00 PM presentation

Location: Hilton Garden Inn, 2000 Bridgepoint Circle, San Mateo

Cost:

Employed/postdocs: \$30 early registration, \$35 regular registration

Unemployed/retired/students: \$15 early registration, \$20 regular registration

Free if you attend just the lectures at 8:00 PM (but please let us know for headcount)

Register at [www.GGPF.org](http://www.GGPF.org) (PayPal is enabled if desired)

After deadline:

Registration not guaranteed, so contact us

Late fee applies if space available -- \$40 regular/employed, \$25

unemployed/student/retired

Deadlines for registration:

End of discounted advance registration Friday, Feb. 17, 11:59 PM

End of regular (full-price) registration Wednesday, Feb. 22, 5:00 PM

Because we must pay the restaurant for the ordered meal, we must ask no-shows to pay for their reservation.

However, penalty-free cancellations are allowed up until the deadline for reservations (Wednesday, Feb. 22, 5:00 PM).

PLEASE NOTE:

We accept cash or checks at the door, but are unable to accept payment by credit card at the event.

You may pay at the door.

Checks may be made to "GGPF"

Please register on the web page, [www.GGPF.org](http://www.GGPF.org)

Or, if necessary, contact:

Len Radzilowski

[lradzilo@te.com](mailto:lradzilo@te.com)

650-361-3264

You should receive confirmation of your registration; if not, please contact us again.

Topic Description

Recent findings from the ion-containing polymer membrane community have taught us the importance of controlled sequencing of ionic groups along polymer chains in the development of ordered polar domains for enhanced transport properties. When compared on an equal ion content basis, a blocked arrangement of ionic groups along polymer chains tends to produce more ordered nano-phase-separated domains while preserving the inherent properties of the unfunctionalized homopolymer over that of analogous random ionomers. Inspired by these demonstrated enhancements, we have begun to explore the

impact of variable post-polymerization sulfonation reactions on the spatial distribution of functional groups in ionomers. Very recently, we have discovered a non-functionalizing solvent for PEEK that allows for a homogeneous sulfonation reaction. Surprisingly, this new solvent also allows for the formation of a thermo-reversible gel. Following a method we previously developed to sulfonate syndiotactic polystyrene (sPS) in the gel state, we are now able to prepare a blocky form of sulfonated PEEK that has a high degree of sulfonation and a high degree of crystallinity. A broader impact of this research involves the first development of PEEK hydrogels and aerogels with remarkable physical properties.

#### Speaker Bio

Robert B. Moore is the Director of the Macromolecular Science and Engineering (MACR) graduate degree program, and a Full Professor in the Department of Chemistry at Virginia Tech. Professor Moore received his Ph.D. in Analytical Chemistry from Texas A&M University, followed by a postdoctoral fellowship in the Department of Chemistry at McGill University in Montreal, Quebec. In 1991, he joined the faculty of the Department of Polymer Science at The University of Southern Mississippi, where he served for 17 years. In 2007, he moved to Virginia Tech to join the faculty in the Department of Chemistry. Research in the Moore group is focused on processing-morphology-property relationships of functionalized, semi-crystalline polymers (specifically ionomers) to understand the role of specific interactions in morphological development. The Moore research group is actively involved in discovery and development of new polymeric materials for applications in proton exchange membrane fuel cells, thermoreversible gels, nanostructured electrodes and electrolytes for batteries, and compatibilized blends and nanocomposites.

\*\*\*\*\*

#### **JLABS, Tuesday Morning, March 7, 2017**

Topic: "Value of Biotechnology Business"

Speaker: John Selig | Managing Partner, Mavericks Capital

Date and Time: Tuesday, March 7, 2017, 9:45 am

Agenda:

9:45am | Registration

10:00am | Presentation and Q&A

11:30am | Lunch and Networking

12:00 | Program close

Location: JLABS @ SSF. 329 Oyster Point Blvd - 3rd Floor. South San Francisco, California

Fees:

Presentation

\$25 | General Public

\$35 | Onsite

Details and registration at <https://www.eventbrite.com/e/the-value-of-a-biotechnology-business-tickets-29593178995?aff=weekly>

#### Topic Description

Biotech companies... do you know your worth? The wise startup company plans their exit from the beginning. In order to properly leverage your exit value you need to understand the different valuation methods, how they are used and who is using them.

John Selig, Managing Partner and co-founder of Mavericks Capital, a healthcare investment bank, will guide you through the maze of sunk costs, sum of parts,

comparables, Discounted Cash Flow (DTC) and Net Present Value (NPV) to help you increase negotiating leverage and make more informed funding decisions.

Join us for an informative and interactive session.

Topics Covered

- The different valuation methodologies and who is using them
- Key approaches in funding for life science companies
- Planning exit strategies and deal structuring from the outset
- How do my expected deal terms relate to my forecast cash flows and how can I use this to make better decisions on licensing timing?

In cooperation with BioPharma Consortium. Visit [www.Biopharmaconsortium.com](http://www.Biopharmaconsortium.com) for more information.

Speaker Bio

John advises life science companies on M&A, licensing and financial strategy. He speaks frequently on topics in valuation, deal term benchmarking, and strategy in the life sciences space, including the Valuation and Finance module at BIO's Executive Management Training course for BD professionals each year and the Valuation lecture at Stanford Medical School's Entrepreneurship Program. Prior to joining Maverick's, John co-lead the Life Sciences Group at Woodside Capital Partners, a boutique investment bank. For the prior 12 years, he advised both Fortune 100 and VC - backed healthcare companies on transaction strategy and valuation at Strategic Decisions Group (SDG), a global management consulting firm, and Keelin Reeds Partners, a life sciences consulting firm. While at Keelin Reeds, John led a partnership and M&A deal term benchmarking effort and has extensive experience in applying that data to yield market-value deal terms for dozens of assets, using the results to provide ongoing support during deal negotiations. Prior to consulting, John was an attorney with Weil, Gotshal and Manges where he focused on M&A and corporate finance. John holds a JD from Stanford Law School, where he was an Associate Editor of Law Review, and a BA, magna cum laude, from Brown University, where he was a member of Phi Beta Kappa (FINRA 24, 63, 79).

\*\*\*\*\*

**UCSC Clinical Trials Course: March 13-17, 2017**

Event: Clinical Trials Essentials: An Intensive One-Week Course  
Event Dates: Monday March 13- Friday, March 17 2017  
03/13/2017 - 8:00am  
Event Location: UCSC Ext 3175 Bowers Avenue, Santa Clara

Event Description

The course benefits anyone working in the biopharmaceutical and medical device industries and the biomedical community who is interfacing with or conducting clinical research, including new clinical research associates and study coordinators; medical directors, physicians, nurses, pharmacists, and other health professionals; biomedical scientists; statisticians and database administrators; and business professionals.

\*\*\*\*\*

**Bio2Device Group, Tuesday Evening, March 14, 2017**

Topic: "Brink of Catastrophe: Catching Addiction Early"  
Speaker: David Deacon, CEO, DxRx Inc

Date and Time: Tuesday, March 14, 2017, 6:00 pm  
Location: Wilson Sonsini Goodrich & Rosati, 650 Page Mill Road, Palo Alto  
Cost:  
\$6 - Students/In-transition - Members only  
\$11 - Early-bird Registration - Members only  
\$20 - Late Registration and Non-Members  
\$25 - Walk-ins  
Register at [www.Bio2DeviceGroup.org](http://www.Bio2DeviceGroup.org)

#### Topic Description

One out of every ten Americans has a condition doctors call Alcohol Use Disorder or AUD. If you have AUD, your choices and activities begin to be changed by your drinking habits. With so many people affected, we should call AUD an epidemic. Instead, most people suffer in silence. Because of that silence, we get a very warped impression of alcoholism. A few late stage cases, like the derelicts passed out in the streets, are hyper-visible, while the millions of early stage cases are invisible. Yet people avoid treatment out of fear of being stigmatized for AUD, and it's all due to visibility bias.

Alcohol abuse disorder must be treated effectively like any other disease. It's not a disease of the willpower. It's a chronic condition that arises when your brain reward systems get "hijacked" by the addictive substance. Some people's neurotransmitter systems are more vulnerable than others, and the more vulnerable ones get locked into the addiction cycle. It is neurotransmitter malfunction that locks in the addiction, and studies show that neural system recovery can take most of a year, depending on severity. Like any addiction, alcoholism continues to get worse if left untreated.

Most people have only two choices of treatment modality today: Alcoholics Anonymous, a support group which is available everywhere but not very effective; and Rehab, a residential dry out approach which is effective near-term but impossible for most people to use. Given these choices, it should be no surprise that so few of the 34 million AUD sufferers get any kind of treatment at all. Out of the big six chronic diseases, AUD stands alone in that barely 7% get treated each year.

What I find most surprising is that effective medical treatment has been available for almost 25 years without being broadly adopted by the medical profession. I am referring to "Medication-Assisted Treatment" with naltrexone, which has been tested and shown effective in multiple clinical trials. Why is this treatment not widely available today? What does it take to make this treatment available to everyone? Can a technology-enabled medical service company break through the barriers?

#### Speaker Bio

David is an entrepreneurial leader who has built four successful startups as founder, member of the board, and line executive in product development, sales, and business development.

As entrepreneur, he developed multiple products leveraging technology to provide new customer value in telecom, diagnostics, and medical devices; as angel investor he has coached dozens of technology companies from concept into commercialization.

David's business leadership includes recognizing market shifts in time to pivot the business focus, hiring standout teams from CEO through Engineer, managing IP portfolios leading to 62 issued patents, and leading an international team for four years in Europe; raised \$50 M from Tier-1 VCs and strategic partners; BS in Electrical Engineering, Massachusetts Institute of Technology and PhD in Physics, Stanford University.

\*\*\*\*\*

**WIB, Thursday Evening, March 16, 2017**

Event: WIB-San Francisco Bay Area Women's History Month Event:

Leveraging Partnerships in the Growing Immuno-Oncology Space,  
Date and Time: Thursday, March 16, 2017, 5:30 p.m. – 8:30 p.m. PST  
Moderator: Stacy Feld, VP, Consumer Venture Investments & External Innovation, J&J Innovation - JJDC  
Panelists: Julie Hambleton, MD, VP and Head of US Medical, Bristol-Myers Squibb  
Sylvaine Cases, PhD, VP of Oncology Scientific Innovation, Janssen R&D and J&J Innovation; Jane Grogan, PhD, Head of Adaptive Tumor Immunity and Principal Scientist, Genentech  
Registration Deadline  
March 13, 2017  
Location: JLABS @ SSF, 329 Oyster Point Blvd., South San Francisco, CA 94080  
Fees: Member - \$25 and Nonmember-\$55  
Register at <http://womeninbio.org/eventdetails.aspx?EventId=30876>

#### Event Description

This event will feature women leading innovation, development, and growth through partnerships at life science companies. As biopharmaceutical companies seek to add novel candidates to their pipeline, immuno-oncology (pharmaceuticals that target the immune system to help fight cancer) has been an active area of focus for venture capital investment, partnerships, and collaborations in the life science sector. Although the immuno-oncology space is still nascent, there has been a steady flow of collaborations announced across a diverse range of deal structures. Panelists will share their perspectives, experience, and lessons learned in evaluating and implementing immuno-oncology partnerships. Come and be inspired by these women leading the way in the biotech industry!

Participants will:

- Hear about trends in immuno-oncology
- Listen to industry leaders describe critical factors for successful partnerships
- Learn about partnership resource needs and life cycle as well as examples of building from synergies
- Be exposed to various types of collaborations and lessons learned in evaluating and implementing these partnerships.

Learn more and register for this event.

\*\*\*\*\*

#### **CABS, Saturday Afternoon, March 18, 2017**

Topic: "NGS for cancer and autoimmune diseases"  
Date and Time: Saturday March 18, 2017 @ 2:00 pm - 4:00 pm  
Location: Hanqi Investment, 1633 Bayshore Hwy, Unit 280, Burlingame, CA 94010  
Cost: free  
Registration: [here](#) (space is limited)  
Register at  
<http://www.cabsweb.org/events/2455515/NGS%20for%20cancer%20and%20autoimmune%20diseases/>

#### Program Description

Presentations:

- Personalized health care for oncology by Craig Cummings, Associate Director, Oncology Biomarker Development, Genentech

- NGS application in immunology studies by Naibo Yang, Director, Immunogenetics, Complete Genomics Inc.

\*\*\*\*\*

Healthcare Event, Friday Morning, Feb. 24, 2017

**EPPICon 2017, Saturday, March 25, 2017**

Event: 11th Annual flagship event of EPPIC Global

Keynote Speakers: Ira Mellman, PhD (Genentech) and D. J. Patil (Chief Data Scientist, White House Office of Science and Technology)

Date and Time: Saturday, March 25, 2017,

8:00 AM: Registration open - Breakfast and Networking

9:00 AM: Opening / Plenary Keynote - Ira Mellman, PhD, Genentech

10:30 AM – 5:00 PM: Panels and Speakers

Location: Crowne Plaza Hotel San Francisco Airport, 1177 Airport Blvd, Burlingame, CA 94010

Registration online: \$100

On-site Registration: \$150

Student/Post Doc Registration Online: \$75\* (Valid student ID to be presented at Conference)

EPPIC Charter Members\*\* / Sponsors\*\* / Event Speakers\*\*

(Registration includes food and beverage - breakfast, lunch, coffee breaks and evening reception)

\* Student/Post Doc promo code "STCON17"

\*\* Renew or Register with Code provided to you: Conference is complimentary

Register at

<https://s07.123signup.com/servlet/SignUpMember?PG=1536045182300&P=15360451911431663100>

Visit [www.eppicon.org](http://www.eppicon.org) for more information

#### Event Description

Since 1998, EPPIC Global has been serving the San Francisco Bay Area life sciences community promoting entrepreneurship, networking, partnering, and mentoring. Join us to hear expert talks and panel discussions on

#### Immunotherapy, Bioinformatics and Diagnostics

If targeted therapies and personalized medicine revolutionized cancer treatment in the last decade, will Immunotherapy be the next big hope during the coming decade?

Have we finally got a handle on big data and where is Bioinformatics headed?

Ditto with regard to Biomarkers and Diagnostics?

Advances in cancer immunotherapy have generated enthusiasm across all fields of oncology. Complimentary/companion diagnostics along with predictive biomarkers are integral to improving patient outcome. In addition, emphasis on personalized medicine and targeted therapies, diagnostics and biomarkers are playing an increasingly important role in drug development. Early adoption of bioinformatics tools can help advance therapeutic candidates.

EPPICon 2017 continues the grand tradition of bringing you the latest advances and opportunities in science and technology.

Get updated on the state of the art in science and business

Form new alliances

Explore investment opportunities

Who Should Attend

Entrepreneurs, Innovators, Researchers, Investors and Professionals (including Service Providers) from Pharma, Biotech, Diagnostics, Devices and Digital Health

OPEN for Registration NOW!!!

[Click here to Register](#)

Immuno-Oncology Panel: Chan Whiting, PhD, Aduro Biotech, Robert Sikorski, MD, PhD, Five Prime Therapeutics, Caroline Breitbach, PhD, Turnstone Biologics, Alex Franzusoff, PhD, PACT Pharma

Bioinformatics Keynote Speaker: Nikesh Kotecha, PhD

Bioinformatics Panel: Arshad Ahmad, Ajay Shah, Richard Bourgan, PhD, Genentech

Devices/Diagnostics: Speaker to be announced

Speed Pitch (Please see below for details)

11:30 AM – 1:15 PM: Speed Networking, Vendor Exhibit and Lunch

5:00 PM: Closing Keynote – D. J. Patil, Chief Data Scientist, White House Office of Science and Technology

Evening Reception and Networking

\*\*\*\*\*

**CABS, Saturday Afternoon, March 25, 2017**

Topic: "Precision Medicine for oncology and immunology"

Date and Time: Saturday March 25, 2017 @ 2:00 pm - 4:00 pm

Location: Hanqi Investment, 1633 Bayshore Hwy, Unit 280, Burlingame, CA 94010

Free

Register at

<http://www.cabsweb.org/registration/2455518/Precision%20Medicine%20for%20oncology%20and%20immunology/>

Presentations:

1. Liquid biopsies in precision drug development by Shidong Jia, Founder and CEO of Predicine Holdings Ltd.

Cancer immunotherapy and targeted therapy offer great promise in precision oncology, where predictive biomarkers have been extensively investigated in various types of cancer patients. The talk will describe development and clinical application of an innovative, next generation sequencing based liquid biopsy test to support cancer immunotherapy clinical trials.

Speaker Bio

Dr. Shidong Jia is the Founder and CEO of Predicine Holdings Ltd, an international precision medicine organization that is committed to developing innovative diagnostics, therapeutics and big data in cancer and other serious diseases. The company operates in California, USA and Shanghai, China. Driven by a passion to improve personalized medicine, Dr. Jia has dedicated the past 21 years to basic, translational, and clinical cancer research. His previous work identified p110beta as novel drug target for PTEN-deficient prostate tumors (Jia S, et al. Nature, 2008), a finding that laid the foundation for the clinical development and testing of p110beta inhibitors in cancers. Most recently, his team at Predicine developed world's first ctRNA and ctDNA combined liquid biopsy test for precision medicine in cancer. A former Scientist, principal investigator and prostate cancer disease area lead at Genentech, Dr. Jia spearheaded the biomarker strategies and drug & diagnostics co-developments efforts in support of clinical oncology pipeline at various stages (i.e., early stage research, late stage research, early clinical development, Phase I and Phase II clinical trials), culminated by the Lifecycle Investment Point (LIP) achievement of driving an investigative drug from global Phase II into Phase III pivotal clinical trial. Prior to joining Genentech, Dr. Jia was Laboratory Head for Oncology Drug Discovery at the Novartis Institutes for BioMedical Research in Cambridge, MA. Dr. Jia serves as the Editor-in-Chief of "Journal of Circulating Biomarkers", Guest Associate Editor of "Frontiers in Oncology", and Members of National Cancer Institute Review Committees and the Italian Ministry of Health - Scientific Research and Health Innovation Review Committee. Dr. Jia is a BayHelix member and receipt of several awards, including the "Young Investigator Award" at the Fourth Asian Congress for Microcirculation in Indonesia and the "P.A.R.T. Investigatorship Award" at the Dana-Farber Cancer Institute, Harvard Medical School in Boston.

2. Towards an Assay of Global Immunocompetence by Holden Maecker, Director, Human Immune Monitoring Center, Stanford

A long-term goal of our laboratory is to define metrics of healthy immune function and the deviations that predict or define disease states. There are many facets of the immune system that can be measured, and few clinically accepted tests of immune function. However, we hypothesize that a comprehensive assessment of the proportions, phenotypes, and functions of specific immune cell subsets in blood should be helpful in defining these metrics. We have therefore defined for this purpose a mass cytometry assay using phorbol myristate acetate (PMA)+ionomycin stimulation of peripheral blood mononuclear cells (PBMC), with staining for approximately 40 cell-surface and intracellular proteins, including lineage markers, cytokines, and other functional markers. Mass cytometry, or CyTOF, is a version of flow cytometry that uses heavy metal ion labels in place of fluorochromes, with

readout by time-of-flight mass spectrometry. The CyTOF platform allows for many more labeled antibodies to be used in combination, with much less spillover between detection channels, compared to conventional flow cytometry. In this talk, I will describe this methodology and how we are applying it currently to the monitoring of patients undergoing cancer immunotherapy. Our goal in these studies is to better tailor immunotherapies to specific patients, and to suggest approaches that might be useful to address those patients with suboptimal immune function.

**Speaker Bio**

Dr. Holden T. Maecker received his PhD from Stanford University, is currently Assoc. Prof. at Microbiology & Immunology department and Director of Human Immune Monitoring Center at Stanford. His research is in the area of T cell response signatures and their association with protection from chronic pathogens and cancer. His lab has published a number of papers on this topic, both alone and in collaboration with other groups, in systems such as CMV, HIV, tuberculosis, and cancer. The Human Immune Monitoring Center (HIMC) is a Stanford core service laboratory, which performs blood processing and standardized assays using flow cytometry, genomics, and immunoassay platforms. For the past five years, his lab has gained extensive experience with CyTOF mass cytometry. In addition to being PI on multiple NIH, industry, and foundation grants, Dr. Maecker serves as a core leader for several cooperative center grants and other large collaborative projects, in which he oversees the use of HIMC assays, including data analysis and interpretation.

\*\*\*\*\*

**EPPICon, Saturday, March 25, 2017**

Event: EPPICon 2017

Location: Crowne Plaza Hotel San Francisco Airport, 1177 Airport Blvd, Burlingame, CA 94010

**Event Description**

The 11th Annual flagship event of EPPIC Global, a San Francisco Bay Area based organization focused on pioneering advances in the life sciences and partnering, mentoring, and networking for professionals.

Featuring talks and panel discussions from leading experts on Immunotherapy, Bioinformatics and Devices

**Who Should Attend**

Entrepreneurs, Innovators, Researchers, Investors and Professionals (including Service Providers) from Pharma, Biotech, Diagnostics, Devices and Digital Health

**Past Speakers at EPPICon**

Kim Bush, Ann Lee, Corey Goodman, Hal Barron, James Sabry, Timothy Moore, Kiran Mazumdar-Shaw, Steven Isaacs and many more...

Stay tuned - Conference registration and additional information coming soon!

EPPICon 2017 Organizing Committee

EPPIC GLOBAL

[www.eppicglobal.org](http://www.eppicglobal.org)

[eppic@eppicglobal.org](mailto:eppic@eppicglobal.org)

(408) 357-0601

\*\*\*\*\*

## **JLABS, Tuesday Morning, March 28, 2017**

Topic: "Meet with ...MPM Capital" Program Overview:

Speakers: Vinay Bhaskar, Ph.D., Principal with MPM Capital;  
Luke Evnin | Managing Director, MPM Capital

Date and Time: Tuesday, March 28, 2017, 10:30 am

Agenda:

10:30am | Registration & Networking

11:00am | Presentation and Q&A

11:45am | Lunch & Networking

12:30-5:00pm | One-on-one Meetings\*

\*Companies must have applied for a one-on-one meeting ahead of time and been approved. Applications are due February 28. Apply Here.

Location: JLABS @ SSF, 329 Oyster Point Blvd - 3rd Floor, South San Francisco,

Fees:

Presentation

\$25 | General Public

\$35 | Onsite

Includes presentation, Q&A, and lunch. All attendees must pay this fee, regardless of one-on-one meeting status. Pre-registration to attend the presentation, Q&A, and lunch will remain open until March 28th (or sold out).

One-on-One Meeting

FREE | Application

FREE | Accepted Companies

Companies must have applied for a one-on-one meeting ahead of time. The one-on-one application period will close on February 28, 2017. Your application will be reviewed and you will be notified of acceptance by March 15, 2017. Acceptance of a one-on-one meeting is not guaranteed as all applications must be approved.

Registration at <https://www.eventbrite.com/e/meet-with-mpm-capital-tickets-29590468889?aff=weekly>

Topic Description

Do you have innovation that will change the face of medicine? MPM Capital is looking for leading scientific research that addresses unmet medical needs across all therapeutic areas. MPM is no stranger to Johnson and Johnson Innovation, JLABS (JLABS) with investments that recently helped 3 Bay Area JLABS companies reach the next level. MPM is now investing two funds, BV2014, a \$400M fund focusing on early stage companies developing therapies for unmet medical needs (Series A and earlier), and the Oncology Impact Fund, a \$470M fund that invests solely in oncology companies of any stage (therapeutics only - no diagnostics). For more information on MPM visit <http://www.mpmcapital.com/>

Vinay Bhaskar, Ph.D., Principal with MPM Capital, will be in attendance to provide an overview presentation on MPM's key areas of interest and venture investment philosophy. Vin will be joined by Luke Evnin to answer any questions and meet with a handful of applicants for one-on-one meetings. To be considered for a one-on-one meeting complete the information required in the link below.

About the Meet with... Series:

The purpose of the Meet with Series events sponsored by JLABS is to help start-up entrepreneurs, as well as the academic community, connect with potential partners, such as big pharma or other investment corporations, through one-on-one meetings. It is also a chance for the featured corporation to outline their specific business development goals and clarify what types of products or research they are interested in and how best to approach them to get the partnering process started. Past participants include the Wellcome Trust, Bill & Melinda Gates Foundation, MedImmune Ventures, Mercury Fund, DARPA's Biological Technologies Office, Correlation Ventures, Breakout Labs, New Enterprise Associates, Canaan Partners, Thomas McNerney & Partners, NCI, NCATS, NINDS, Allegory Venture Partners, Clarus Ventures, Johnson & Johnson Innovation, California Institute for Regenerative Medicine, Astellas Venture Management, and OrbiMed.

Do you have innovation that will change the face of medicine? MPM Capital is looking for leading scientific research that addresses unmet medical needs across all therapeutic areas.

#### Speaker Bios

Luke Evnin, Ph.D., co-founded MPM with Ansbert Gadicke in 1997 and opened the San Francisco office in 1999. The MPM team they have led has been the inspiration and driving force behind building companies such as Biomarin (BMRN), CoStim Pharmaceuticals (acquired by Novartis: NVS), Epizyme (EPZM), Idenix (acquired by Merck: MRK), Pacira (PCRX), Pharmasset (acquired by Gilead: GILD) and Radisu (RDUS). MPM believes that these companies are among the biggest successes in biotech history - companies that ultimately resulted in helping thousands of patients live longer with vastly improved lives. Luke was lead investor and has served on the boards of several of MPM's most successful investments including CoStim Pharmaceuticals, Idun Pharmaceuticals, and Pacira.

Prior to co-founding MPM, Luke honed his skills as a venture capitalist beginning in 1990 at Accel Partners where he focused on emerging healthcare companies. Luke's passion for drug discovery began in college where he received his A.B. in Molecular Biology from Princeton University. He advanced his technical training and launched his interest in curing disease with his doctoral study in Department of Biochemistry at the University of California - San Francisco. Luke's passion for discovering and pushing forward groundbreaking drug discovery companies inspires his work and that of his team. Luke has devoted significant efforts since 2000 to working with Scleroderma Research Foundation, serving as Chairman since 2002. Luke also devotes energy to the External Advisory Board at the Lewis-Sigler Institute for Quantitative Genomics at Princeton, serves on the External Advisory Boards for QB3 at UCSF, the Masters in Translation Medicine program at UCSF, and Boston University Scleroderma CORT.

Vinay Bhaskar, Ph.D., joined MPM in 2016 after leading External R&D for the Oncology therapeutic area at Amgen. In this role, Vin was instrumental in forging collaborations with companies such as Kite Pharma, Merck, and Xencor. During this time he also led internal immuno-oncology strategy discussions and served as executive sponsor and/or board observer for several Amgen Ventures investments, including Surface Oncology, Precision BioSciences and Tizona Therapeutics, a company founded by MPM. Vin joined Amgen through its acquisition of Onyx Pharmaceuticals, where he led preclinical search, evaluation, and diligence for licensing and acquisition opportunities on the Asset Acquisition Team.

Prior to joining Onyx, Vin held a variety of roles of increasing responsibility in Discovery Research at Portola Pharmaceuticals, XOMA, PDL Biopharma and Eos Biotechnology. In these roles, he initiated and led multiple preclinical project teams

and functional groups focused on biologies and spanned oncology, inflammation and cardio metabolic disease. Through these endeavors, Vin has gained broad expertise across all phases of drug discovery, early development and process sciences. Vin holds a Ph. D. in Biochemistry from UCLA and a B.S. in Biochemistry from UC Davis.

\*\*\*\*\*

**Biomedical Engineering Society, Wednesday, March 29, 2017**

Event: 8th Annual Bay Area Biomedical Device Conference-Medical Devices in the Connected World

Date and Time: Wednesday, March 29, 2017, 7:30 am

Location: SJSU Student Union Ballroom, San Jose State University

Please take advantage of the reduced early registration which ends on March 16, 2017 at 5:00 pm. PST.

Visit our website at [www.biomedconference.org](http://www.biomedconference.org) for more details or email [info@biomedconference.org](mailto:info@biomedconference.org) if you have any questions.

Register at <http://www.biomedconference.org/register>

Event Description

The Biomedical Engineering Society at San Jose State University (SJSU) is happy to announce the 8th Annual Bay Area Biomedical Device Conference!

Some exciting features of this conference include:

- An expert biomedical plenary speaker
- Informative parallel sessions
- Interactive Industry & CEO Panels
- Student Research Posters
- Sponsors and representatives from various biomedical companies
- Wine & cheese networking reception
- & More!

\*\*\*\*\*

**PBSS Workshop, Thursday Afternoon, March 30 2017**

Event: "Best CMC Practices for Successful Drug Development and Commercialization: Leveraging QbD and risk-based strategies for efficient CMC development"

Speakers: Prabu Nambiar, Edward Ciolkowski, James Bush (Syner-G Pharma Consulting)

Date and Time: Thursday, March 30, 2017, 12:30-5:00 pm Registration fee (US\$): Regular: \$125;

Academic: \$75; For unemployed & students: \$25; For vendor-show reps: \$25; For major-sponsor rep (incl lunch): \$0; For others, details available upon online login.

Location: SF Bay Area: Foster City Crowne Plaza

Registration: <http://www.pbss.org/asp/eventInfo.aspx?eID=528>

Further Information:

Registration deadline: 3/28/2017 (it will close sooner if the seating cap is reached)

[support@PBSS.org](mailto:support@PBSS.org)

[www.PBSS.org](http://www.PBSS.org)

\*\*\*\*\*

**JLABS, Tuesday Morning, April 18, 2017**

Topic: "Meet with the Gates Foundation"

Speaker: Charlotte Hubbert, PhD | Partner, Gates Foundation Venture Capital

Location: JLABS @ SSF, 329 Oyster Point Blvd - 3rd Floor, South San Francisco, California

Date and Time: Tuesday, April 18, 2017, 10:30 am

Agenda:

10:30am | Registration & Networking

11:00am | Company Presentation and Q&A

11:45am | Lunch & Networking

12:45-5:00pm | One-on-one Meetings\*

\*Companies must have apply ahead of time and be approved for a one-on-one meeting. Application period ends March, 13, 2017. Apply Here.

Fees:

Presentation

\$25 | General Public

\$35 | Onsite

Includes presentation, Q&A, and lunch. All attendees must pay this fee, regardless of one-on-one meeting status. Pre-registration to attend the presentation, Q&A, and lunch will remain open until 12:30pm on April 18th (or sold out).

One-on-One Meeting

FREE | Application

FREE | Accepted Companies

Companies must have applied for a one-on-one meeting ahead of time. The one-on-one application period will close on March 13, 2017. Your application will be reviewed and you will be notified of acceptance by March 30, 2017. Acceptance of one-on-one meeting is not guaranteed as all applications must be approved

Registration at <https://www.eventbrite.com/e/meet-with-the-gates-foundation-tickets-29533732188?aff=weekly>

Program Overview:

The path out of poverty is paved with access to quality healthcare. Do you have solutions that will make a difference? The Bill & Melinda Gates Foundation is advancing science and technology to save lives in developing countries. The Foundation works with partners to deliver proven tools—including vaccines, drugs, and diagnostics—and discover ground breaking new solutions that are affordable and reliable. Focus areas for investments center on infectious diseases including HIV, polio, TB, dengue and malaria, as well as diagnostics and health IT ideas that bring health interventions to people who need them most.

Charlotte Hubbert, Partner with Gates Foundation Venture Capital, will be in attendance to provide an overview presentation on the Foundation's key areas of interest and venture investment philosophy. Gates Foundation Venture Capital operates under the Program Related Investments group at the Bill & Melinda Gates foundation, which manages a \$1.5B allocation for private sector investment. Charlotte will be on hand to meet with a handful of applicants one-on-one after the presentation. To be considered for a one-on-one meeting complete the information required at the link below.

Speaker Bio

Charlotte Hubbert is a Partner with Gates Foundation Venture Capital, investing innovative technologies that support The Bill & Melinda Gates Foundation initiatives in Global Health and Agriculture. Prior to joining the Gates Foundation, Charlotte was a Vice-President at H.I.G. BioVentures focusing on investment opportunities in the life sciences, including therapeutics, diagnostics and medical devices at all stages of

development. She was BOD observer at Cardeas Pharma and Alder Biopharmaceuticals. Charlotte started her career in early stage biotech investing at Accelerator Corporation, an investment vehicle focused on identifying, evaluating, financing and managing emerging therapeutic technologies. During her tenure, Charlotte was involved in the strategic development and management of five companies, including Oncofactor, Groove Biopharma, Acylin Therapeutics, Xori and Pharmselex. Charlotte currently serves as an observer on the board of directors of Synlogic, Sera Prognostics and Lodo Therapeutics. Charlotte earned a B.S. in Microbiology from the University of Washington and a Ph.D. in Pharmacology and Cancer Biology from Duke University. She did her post-doctoral work in stemcells and regenerative medicine at the Institute for Stem Cells and Regenerative Medicine at the University of Washington. Charlotte is a member of the Kauffman Society of Fellows (Class 14).  
Connect with Charlotte: [Connect on LinkedIn](#)

#### About the Meet with... Series:

The purpose of the Meet with Series events sponsored by JLABS is to help start-up entrepreneurs, as well as the academic community, connect with potential partners, such as big pharma or other investment corporations, through one-on-one meetings. It is also a chance for the featured corporation to outline their specific business development goals and clarify what types of products or research they are interested in and how best to approach them to get the partnering process started. Past participants include the Wellcome Trust, Bill & Melinda Gates Foundation, MedImmune Ventures, Mercury Fund, DARPA's Biological Technologies Office, Correlation Ventures, Breakout Labs, New Enterprise Associates, Canaan Partners, Thomas McNerney & Partners, NCI, NCATS, NINDS, Allegory Venture Partners, Clarus Ventures, Johnson & Johnson Innovation, California Institute for Regenerative Medicine, Astellas Venture Management, and OrbiMed.

\*\*\*\*\*

#### **PBSS Symposium, Monday, April 24, 2017**

*Topic: "Mechanistic Drug Metabolism for Drug Candidate Optimization – A Mini-symposium for Medicinal Chemists and DMPK Scientists"*

Organizers: Cyrus Khojasteh and Donglu Zhang (Genentech)

Date and Time: April 24, 2017, 8:45-17:00

Location: Crowne Plaza, Foster City, CA

Registration fee (USD): Minisymposium fee: \$195;

Registration: <http://www.PBSS.org>

Registration deadline: 4/20/2017 (it will close sooner if the seating cap is reached)

#### Topic Description

Drug metabolism and pharmacokinetics (DMPK) plays an integral role in drug discovery. At drug discovery stage, mechanistic drug metabolism studies contribute to generating drug candidates with optimal ADME properties and in some cases it allows for overcome potential drug development obstacles such as toxicity and DDI that are often encountered in drug discovery and development. In this one-day symposium, multiple examples will be presented to illustrate the utilities of mechanistic drug metabolism in moving discovery and development programs forward. Medicinal chemists and drug metabolism scientists should greatly be benefited from participating in this symposium.

Tentative topics and speakers:

Morning: 8:45-12:00

Overview on drug metabolism and its role in lead optimization - Cyrus Khojasteh, Genentech  
Hepatocyte spheroid models and applications in drug metabolism - Jinping Gan, BMS  
Sponsor presentation  
Drug metabolism tools to assess bioactivation potential of drug candidates - minimizing metabolism-related DILI or genotoxicity - Zhoupeng Zhang, Merck  
Prediction of circulating drug metabolites - Ming Hu, University of Houston

Afternoon: 1:15-5:00

Inhibition of endogenous metabolic pathways leading to toxicities - Donglu Zhang, Genentech  
Sponsor presentation  
Discovery of Bioavailable Pim Inhibitors by Mitigating Intestinal Metabolism – Gina Wang, Genentech  
Metabolism-based structure-activity relationship analysis for identification of a PI3K inhibitor clinical candidate devoid off target hepatotoxicity - Raju Subramanian, Gilead  
Minimizing reversible and time-dependent CYP inhibition of NAMPT (nicotinamide phosphoribosyltransferase) inhibitors - Mark Zak, Genentech  
Carboxylic acid bioactivation via glucuronides/acyl CoA's and application in drug discovery – Mark Grillo, Amgen